A new position paper from noted thought leaders and the Association of Clinical Research Professionals provides the much-needed voice of the clinical trial professional.

The popularity of decentralized clinical trials (DCTs) is surging, especially among patients. Harnessing technology of all kinds, these trials provide an attractive alternative to the old-style, site-anchored system on which traditional clinical trials have rested. They also have the potential to provide better, more timely data since that data is primarily collected under real-life situations and often available more quickly to monitoring teams, according to Kristin Mauri, Director of Solution Services, Remarque Systems.

ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally NEW YORK, July 1, 2021 /PRNewswire/ — ObvioHealth, a global Virtual Research Organization (VRO), announces it has raised $31 million in its latest round of financing. The round was led by two new partners: Dedalus Group, an international healthcare IT and […]

Florence Healthcare’s Senior Implementation Manager Amanda Korey presents a roadmap that not only fosters collaboration between sites, sponsors and CROs, but also results in robust user adoption across all stakeholder groups.

Thermo Fisher Scientific Inc. is acquiring contract researcher PPD Inc. for $17.4 billion as the medical device maker adds more muscle to the company’s pharmaceutical services business.

Large vaccine trials that are extensive both in size and scope tax the resources of sponsors and contract research organizations (CROs), particularly when the trials seek to compress a process that ordinarily takes years. Rapid but safe implementation of these vaccine studies’ new protocols is pushing trial design to the limit.

Syneos Health announced an agreement to acquire Synteract, a full-service contract research organization (CRO) focused on the biopharmaceutical industry.

The UK government’s Covid-19 Vaccine Taskforce and the contract research company Open Orphan announced a $13 million (£10 million) plan to test investigational vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes Covid-19.

Andrea Bastek – Director of Innovation at Florence, the largest eISF + Remote Site Access platform in clinical research – discusses three ways in which sponsors and CROs can increase compliance with a purpose-built, site-centric, remote access platform.

Precision for Medicine – the first comprehensive, fully integrated biomarker-driven clinical research services organization – announced that veteran healthcare leader Mairead Kehoe was named the CRO’s new Executive Vice President, responsible for overseeing global clinical solutions delivery.